SIM is a BCL11ainhibitor and ROM is a HDAC inhibitor and both of these drugs are Food and Drug Administration (FDA)-approved forhypercholesterolemia and cutaneous T-cell lymphoma respectively. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.